Home » Depomed Petition Urges FDA to Stay Approvals of Nucynta ER ANDAs
Depomed Petition Urges FDA to Stay Approvals of Nucynta ER ANDAs
A Depomed citizen petition claims pending ANDAs for Nucynta ER don't comply with FDA rules.
Citing a recently amended use code, Depomed is urging the FDA to stay final approvals of tapentadol ANDAs that rely on a section viii statement, rather than a patent certification for its’130 patent. The new use code completely overlaps both of the drug's indications, making it impossible to carve them out of the label via a section viii statement, it argues.
Depomed updated the code after purchasing the drug from Johnson & Johnson last March because it found that the ’130 patent claims “were actually much broader than what was reflected in the use code then on file in the Orange Book.”
Upcoming Events
-
21Oct